FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Erfanian Hamid</u>					2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ ENZ ]									tionship of R all applicabl Director		Person(s) to Issuer		
(Last)	(First	`	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 11/23/2022							X	Officer (gi below)	•		Other (specify below)		
C/O ENZO BIOCHEM, INC 81 EXECUTIVE BLVD., SUITE 3					If Amendment, Date of Original Filed (Month/Day/Year)							Chief Executive Officer  6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) FARMINGDALE NY 11735			_	varioticinotis, pare di Origina i ned (wortumpayi real)								X						
(City)	(State	e) (.	Zip)															
		T	able I - Nor	ı-Deriv	ative S	ecuritie	s Acc	uired, D	isp	osed o	f, or Bene	fici	ally Ow	ned				
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 and 5)			5. Amount Securities Beneficially Following F	Owned Form: or Indeported (Instr.		ership Direct (D) rect (I) 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount (A) or (D)		Price	(Instr. 3 and				(mstr. 4)		
Common Stock, \$0.01 Par Value <sup>(1)</sup>				11/23	23/2022		P		100,0	00 A		\$1.97	97 374,600		600 D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yes	Cod	nsaction le (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (In 3 and 4)		ying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	ly i	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Cod	e V	(A)	(D)	Date Exercisable		xpiration ate	Title	Νι	mount or umber of nares		Transaction(s) (Instr. 4)			
Stock Option (to acquire Common Stock)	\$1.97	11/23/2022		А		300,000		11/23/2023	11	1/23/2027	Common Stock	3	00,000	\$0	300,000	(2)	D	
Stock Option (to acquire Common Stock)	\$3.39							11/08/2022	11	1/08/2026	Common Stock	7	00,000		700,000	(3)	D	

## Explanation of Responses:

- 1. The Reporting Person was granted Restricted Stock Units that will vest in three equal installments, beginning on November 23, 2023.
- 2. The Reporting Person was granted 300,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 23, 2023.
- 3. The Reporting Person was granted 700,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 8, 2022.

/s/ Hamid Erfanian

11/28/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.